Lantern Pharma Stock Performance
| LTRN Stock | USD 3.21 0.10 3.22% |
The company secures a Beta (Market Risk) of 1.82, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lantern Pharma will likely underperform. At this point, Lantern Pharma has a negative expected return of -0.12%. Please make sure to verify Lantern Pharma's total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Lantern Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lantern Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 3.22 | Five Day Return 3.88 | Year To Date Return (23.02) | Ten Year Return (78.53) | All Time Return (78.53) |
1 | Disposition of 34731 shares by Fletcher Aaron G.l. of Lantern Pharma at 4.4 subject to Rule 16b-3 | 10/11/2024 |
2 | Lantern Pharmas Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA | 10/15/2024 |
3 | Lantern Pharma to Host Participate in Two Public Webinars During October | 10/21/2024 |
4 | Lantern Pharma to Report Third Quarter 2024 Operating Financial Results on November 7th, 2024 at 430 p.m. ET | 10/31/2024 |
5 | Insider Trading | 11/01/2024 |
6 | Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board | 11/05/2024 |
7 | Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates | 11/07/2024 |
8 | Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients | 11/19/2024 |
9 | LTRN Stock Earnings Lantern Pharma Misses EPS for Q1 2024 - MSN | 11/20/2024 |
10 | Lantern Pharma Starlight Therapeutics Present LP-184 Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology 2024 Highlighting ... | 11/26/2024 |
| Begin Period Cash Flow | 37.7 M |
Lantern |
Lantern Pharma Relative Risk vs. Return Landscape
If you would invest 366.00 in Lantern Pharma on September 1, 2024 and sell it today you would lose (45.00) from holding Lantern Pharma or give up 12.3% of portfolio value over 90 days. Lantern Pharma is currently does not generate positive expected returns and assumes 4.1322% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Lantern, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lantern Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lantern Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lantern Pharma, and traders can use it to determine the average amount a Lantern Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0302
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LTRN |
Estimated Market Risk
| 4.13 actual daily | 36 64% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lantern Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lantern Pharma by adding Lantern Pharma to a well-diversified portfolio.
Lantern Pharma Fundamentals Growth
Lantern Stock prices reflect investors' perceptions of the future prospects and financial health of Lantern Pharma, and Lantern Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lantern Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 6.86 M | ||||
| Shares Outstanding | 10.78 M | ||||
| Price To Book | 1.30 X | ||||
| EBITDA | (15.79 M) | ||||
| Net Income | (15.96 M) | ||||
| Cash And Equivalents | 62.15 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 234.47 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 12.38 X | ||||
| Book Value Per Share | 3.82 X | ||||
| Cash Flow From Operations | (14.35 M) | ||||
| Earnings Per Share | (1.78) X | ||||
| Market Capitalization | 34.62 M | ||||
| Total Asset | 43.65 M | ||||
| Retained Earnings | (55.24 M) | ||||
| Working Capital | 40.66 M | ||||
About Lantern Pharma Performance
By examining Lantern Pharma's fundamental ratios, stakeholders can obtain critical insights into Lantern Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Lantern Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.6 K | -1.7 K | |
| Return On Tangible Assets | (0.37) | (0.38) | |
| Return On Capital Employed | (0.44) | (0.41) | |
| Return On Assets | (0.37) | (0.38) | |
| Return On Equity | (0.39) | (0.37) |
Things to note about Lantern Pharma performance evaluation
Checking the ongoing alerts about Lantern Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lantern Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lantern Pharma generated a negative expected return over the last 90 days | |
| Lantern Pharma has high historical volatility and very poor performance | |
| Net Loss for the year was (15.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lantern Pharma currently holds about 62.15 M in cash with (14.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lantern Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from businesswire.com: Lantern Pharma Starlight Therapeutics Present LP-184 Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology 2024 Highlighting Novel Synthetic Lethality |
- Analyzing Lantern Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lantern Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Lantern Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lantern Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lantern Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lantern Pharma's stock. These opinions can provide insight into Lantern Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Return On Assets (0.28) | Return On Equity (0.45) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.